Vaccinia

Vaccinia virus is a large, complex, enveloped virus belonging to the poxvirus family. It has a linear, double-stranded DNA genome approximately 190 kbp in length, and which encodes for approximately 250 genes. The dimensions of the virion are roughly 360 × 270 × 250 nm. Vaccinia virus is well-known for its role as a vaccine that eradicated the smallpox disease, making it the first human disease to be successfully eradicated by mankind. This endeavour was carried out by the World Health Organization under the Smallpox Eradication Program. Post eradication of smallpox, scientists study Vaccinia virus to use as a tool for delivering genes into biological tissues . Moreover, due to recent concerns about smallpox resurfacing as a possible agent for bioterrorism, scientists have renewed their interests in studying Vaccinia virus. (From the Wikpedia article Vaccinia.)

Download PDF containing detailed information.

Recent Publications on Vaccinia:
Antiangiogenic arming of an oncolytic vaccinia virus enhances antitumor efficacy in renal cell cancer models. Oncolytic vaccinia viruses have shown compelling results in preclinical...	13th November, 2009	Cancer Gene Therapy Group, Molecular Cancer Biology Program &	J Virol. 2009 Nov 11. DOI Direct Link
Corrections to Multidentate Small-Molecule Inhibitors of Vaccinia H1-Related (VHR) Phosphatase Decrease Proliferation of Cervix Cancer Cells. Oncolytic vaccinia viruses have shown compelling results in preclinical...	13th November, 2009		J Med Chem. 2009 Nov 11. DOI Direct Link
Vaccinia virus A43R gene encodes an orthopoxvirus-specific late non-virion type-1 membrane protein that is dispensable for replication but enhances intradermal lesion formation. The vaccinia virus A43R open reading frame encodes a 168-amino acid...	11th November, 2009	Laboratory of Viral Diseases, National Institute of Allergy and Infectious	Virology. 2009 Nov 7. DOI Direct Link
The extract of inflamed rabbit skin induced by inoculation of vaccinia virus possesses antioxidant and neuroprotective effects in acute ischemic stroke. Acute cerebral ischemia remains a major cause for death and disability but...	11th November, 2009	State Key Laboratory of Pathogen and Biosecurity, Beijing, China.	J Stroke Cerebrovasc Dis. 2009 Nov-Dec;18(6):475-81. DOI Direct Link
A mouse-based assay for the pre-clinical neurovirulence assessment of vaccinia virus-based smallpox vaccines. Post-vaccinal encephalitis, although relatively uncommon, is a known...	10th November, 2009	FDA, Division of Viral Products, Building 29A, Room 2C-20, Lincoln Drive,	Biologicals. 2009 Nov 5. DOI Direct Link
→View more research publications.

Press Releases About Vaccinia:
Aethlon Medical to Present at the 2009 RedChip Small-Cap Investor Conference on June 16, 2009	28th May, 2009	Aethlon Medical, Inc.	SAN DIEGO, May 28 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that the Chairman and CEO, James A. Joyce, will present at the 2009 RedChip Small-Cap
Aethlon Medical Discloses New HIV/AIDS Treatment Data	5th May, 2009	Aethlon Medical, Inc.	SAN DIEGO, May 5 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) today disclosed new data resulting from its recent "first-in-human" application of the Aethlon
Aethlon Medical Confirms Hemopurifier(R) Is a Treatment Candidate Against Swine Flu Virus	30th April, 2009	Aethlon Medical, Inc.	SAN DIEGO, April 30 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) confirmed today that the Aethlon Hemopurifier(R) is a candidate to treat the H1N1 Swine flu virus. The
Aethlon Medical Announces Engagement of RedChip Companies to Initiate Investor and Media Relations Programs	21st April, 2009	Aethlon Medical, Inc.	SAN DIEGO, April 21 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD), developer of the Hemopurifier(R), a first-in-class medical device to treat infectious disease, today
Aethlon Medical Announces CEO Interview and Corporate Presentation Available Online	8th April, 2009	Aethlon Medical, Inc.	SAN DIEGO, April 8 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc. (OTC Bulletin Board: AEMD) announced today that the videotaped CEO television interview and corporate presentation made by Chairman

BioNews Results for Vaccinia:
Erratum: Corrections to Multidentate Small-Molecule Inhibitors of Vaccinia H1-Related (VHR) Phosphatase Decrease Proliferation of Cervix Cancer Cells	Journal of Medicinal Chemistry:  Nov 11 2009 8:43PM Matching: vaccinia
Laboratory-Acquired Vaccinia Virus Infection -- Virginia, 2008	Medscape:  Nov 11 2009 8:12PM Matching: vaccinia
Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX	Pharma Live:  Nov 7 2009 10:24PM Matching: vaccinia
Transgene: First Patient enrolled in Phase I Trial of TG4023 for	PharmiWeb:  Nov 6 2009 5:33AM Matching: vaccinia
Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX	Freshnews.com:  Nov 6 2009 3:07PM Matching: vaccinia
Promote your company here: BioNewsCast - Press Release Distribution	→View more news.

Vaccinia Clinical Trials:
Evaluation and Treatment of Eye Complications of Vaccinia Vaccination

Vaccinia Patents:
US Patent No.	Title
7608704	Secreted proteins
7611868	Recombinant modified adenovirus fiber protein
7611884	Toxoplasma gondii nucleic acid molecules
7611892	Prostate-specific or testis-specific nucleic acid molecules, polypeptides, and diagnostic and therapeutic methods
7611897	AP1 amine oxidase variants
→View more patents.

Companies working in the area of Vaccinia from Bioportfolio's Biocorporate database :
Company Name
Transgene TRANSGENE is a leading integrated gene therapy company, dedicated to the discovery and development of gene delivery technologies and gene therapy products for the treatment of acquired and inherited... www.transgene.fr/        View full profile
BioDETECT BioDETECT's compact, portable flow cytometerers are today used to assists a.o.: wineries and breweries to analyse and detect yeast, water works to verify water filtration processes, pharmaceutical... www.biodetect.biz/        View full profile
Omrix Biopharmaceuticals We aim to develop novel technologies to provide safer and more effective options to patients in areas with substantial unmet medical needs, particularly in the areas of biosurgical and passive... www.omrix.com/index.asp        View full profile
→View more Vaccinia related companies.

BioPortfolio Ltd. offers e-mail and postal lists for Vaccinia scientists - we have details of around 1200 individuals working on Vaccinia .